TABLE 1

Incidence of oesophagitis and pneumonitis observed in selected recent trials

Toxicity: CTCAEPneumonitis %Oesophagitis %
Any gradeGrade 3–4Any gradeGrade 3–4
PROCLAIM: standard therapy [96]10.72.650.720.6
RTOG 0617: 60 Gy [97]Acute 11.1; late 9.8Acute 5.5; late 1.245.16.9
RTOG 0617: 74 Gy [97]Acute 14.5; late 3.9Acute 3.4; late 1.154.117
KCSG-LU05–04: CRT phase [98]2.4079.39.5
CONVERT: LD-SCLC, once daily [99]Acute 22.4; late 32.6Acute 1.6; late 2.6Acute 74; late 18.5Acute 19.1; late 1.7
CONVERT: LD-SCLC, twice daily [99]Acute 22; late 31Acute 1.6; late 2.4Acute 81.1; late 11.7Acute 18.5; late 0
PACIFIC: durvalumab [15]33.93.4
PACIFIC: placebo [15]24.82.6
NICOLAS: nivolumab [100]42.510.427.56.5

CTCAE: Common Terminology Criteria for Adverse Events; CRT: chemoradiotherapy; LD-SCLC: limited disease small cell lung cancer.